MorphoSys in-licenses first clinical compound from Xencor
This article was originally published in Scrip
In its first in-licensing of a clinical compound, MorphoSys of Germany has obtained a worldwide exclusive licence to a monoclonal antibody in Phase I development from US-based Xencor.
You may also be interested in...
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.